Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Varicella zoster virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    65 result(s) found for: Varicella zoster virus. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2005-005825-75 Sponsor Protocol Number: 105909 MeMuRu-OKA 047 Start Date*: 2006-03-20
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline s GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and ...
    Medical condition: Active immunisation against mumps, measles, rubella and varicella
    Disease: Version SOC Term Classification Code Term Level
    6.1 10046980 PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002669-19 Sponsor Protocol Number: X04-VAR-402 Start Date*: 2004-12-23
    Sponsor Name:AVENTIS PASTEUR MSD S.P.A.
    Full Title: A double-blind, randomised, controlled, multi-centre safety study of a refrigerator-stable formulation of VARIVAX® in healthy 12 to 15 month-old infants.
    Medical condition: Active immunisation against varicella
    Disease: Version SOC Term Classification Code Term Level
    6.1 10046980 PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003535-30 Sponsor Protocol Number: 200147 Start Date*: 2015-10-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals’ Varilrix HSA-free varicella vaccine and Varilrix™ given as a 2 dose course in the secon...
    Medical condition: Vaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10069613 Varicella immunisation PT
    19.0 10042613 - Surgical and medical procedures 10069628 Varicella immunization LLT
    19.0 100000004848 10063315 Varicella zoster virus DNA test positive LLT
    19.0 10021881 - Infections and infestations 10046983 Varicella zoster LLT
    19.0 10021881 - Infections and infestations 10046980 Varicella PT
    19.0 100000004858 10050331 Varicella-like rash LLT
    19.0 100000004848 10063144 Varicella zoster virus serology positive LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2005-006065-14 Sponsor Protocol Number: 105908 Start Date*: 2006-04-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline's (GSK) Biologicals' measles-mumps-rubella-varicella candidate vaccine (MeMuRu-OKA) and ...
    Medical condition: Healthy male and female children between 15 months and 6 years of age who previously received an MMR vaccine will receive one dose of MMR + V or MMRV. A second dose of varicella vaccine will be giv...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001332-22 Sponsor Protocol Number: RG_12-201 Start Date*: 2013-06-20
    Sponsor Name:University of Birmingham
    Full Title: PEPtalk 2: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer
    Medical condition: Exposure to Varicella by children who have cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10046980 Varicella PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001608-37 Sponsor Protocol Number: 115555MMRV-063 Start Date*: 2011-12-16
    Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS SA
    Full Title: Open, randomised, controlled, multicenter Phase IIIb study to evaluate the immune response and safety, after the administration of GlaxoSmithKline Biologicals live attenuated measles mumps rubell...
    Medical condition: Vaccination of children from the age of 9 months up to 12 years inclusive against measles, mumps, rubella and varicella diseases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10028257 Mumps PT
    14.1 10021881 - Infections and infestations 10046980 Varicella PT
    14.1 10021881 - Infections and infestations 10039252 Rubella PT
    14.1 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005319-30 Sponsor Protocol Number: 217917 Start Date*: 2022-11-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow-up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of imm...
    Medical condition: Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    21.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    20.1 10021881 - Infections and infestations 10030865 Ophthalmic herpes zoster PT
    20.0 10021881 - Infections and infestations 10063491 Herpes zoster oticus PT
    21.1 10021881 - Infections and infestations 10075611 Varicella zoster virus infection PT
    20.0 10021881 - Infections and infestations 10074297 Herpes zoster cutaneous disseminated PT
    23.1 10021881 - Infections and infestations 10080516 Herpes zoster reactivation PT
    23.1 10021881 - Infections and infestations 10084396 Disseminated varicella zoster virus infection PT
    20.0 10021881 - Infections and infestations 10072210 Genital herpes zoster PT
    20.1 10021881 - Infections and infestations 10061208 Herpes zoster infection neurological PT
    20.0 10021881 - Infections and infestations 10074259 Herpes zoster meningitis PT
    20.0 10021881 - Infections and infestations 10074248 Herpes zoster meningoencephalitis PT
    20.0 10021881 - Infections and infestations 10074243 Varicella zoster oesophagitis PT
    21.1 10021881 - Infections and infestations 10074254 Varicella zoster pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) EE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002676-41 Sponsor Protocol Number: 100388,103494,104105,104106 Start Date*: 2005-05-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (Varilrix) given on ...
    Medical condition: Healthy children between 12-22 months (including the day before the 23-month birthday) of age at the time of vaccination with no history of measles, mumps, rubella and varicella diseases/vaccination.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10028257 Mumps PT
    14.1 10021881 - Infections and infestations 10046980 Varicella PT
    14.1 10021881 - Infections and infestations 10039252 Rubella PT
    14.1 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) SK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020150-34 Sponsor Protocol Number: V212-001-01 Start Date*: 2010-10-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet...
    Medical condition: Incidence of Herpes Zoster in recipients of Autologous HCTs
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) SE (Completed) CZ (Completed) GB (Completed) LT (Completed) IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004442-25 Sponsor Protocol Number: CFAM810B2304 Start Date*: 2016-04-12
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A multicenter, open-label, single-arm, two-step study to evaluate the safety and single-dose pharmacokinetics of famciclovir and multiple-dose safety after administration of famciclovir oral pediat...
    Medical condition: Chickenpox Herpes Zoster
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004020-20 Sponsor Protocol Number: V211-022 Start Date*: 2007-12-10
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019974 Herpes zoster LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023156-89 Sponsor Protocol Number: V212-011 Start Date*: 2011-02-24
    Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc
    Full Title: Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica. A Phase III Rando...
    Medical condition: Incidence of Herpes Zoster in adults with solid tumor or hematologic malignancy Incidencia de Herpes Zoster en pacientes adultos con tumor sólido o neoplasia hematológica.
    Disease: Version SOC Term Classification Code Term Level
    13 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) CZ (Completed) GB (Completed) SK (Completed) AT (Completed) BE (Completed) EE (Completed) LT (Completed) GR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002313-11 Sponsor Protocol Number: V212-009-00 Start Date*: 2012-01-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease
    Medical condition: Prevention of herpes zoster in adults with autoimmune disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) EE (Completed) DK (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000343-10 Sponsor Protocol Number: V211-020-00 Start Date*: 2007-11-20
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥60 Years of Age
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012458-19 Sponsor Protocol Number: ZTV03C Start Date*: 2009-10-15
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: An open-label, randomised, comparative, multicentre study of the immunogenicity and safety of ZOSTAVAX® when administered by intramuscular route or subcutaneous route to subjects ≥50 years of age
    Medical condition: Not applicable as Prevention of herpes zoster ("zoster" or shingles) and herpes zoster-related post-herpetic neuralgia (PHN).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-000344-26 Sponsor Protocol Number: V211-012-00 Start Date*: 2007-06-04
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in s...
    Medical condition: herpes zoster, pneumococcal infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000965-30 Sponsor Protocol Number: 204486 Start Date*: 2016-02-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered int...
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10019982 Herpes zoster NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) CZ (Completed) GB (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014268-20 Sponsor Protocol Number: VZV01 Start Date*: 2009-12-24
    Sponsor Name:Erasmus MC
    Full Title: VZV vaccination to prevent herpes zoster after transplantation
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    12.0 10019974 Herpes zoster LLT
    12.0 10036897 Prophylactic vaccination LLT
    12.0 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001910-27 Sponsor Protocol Number: V210-A03 Start Date*: 2019-07-02
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantl...
    Medical condition: Prevention of varicella in individuals 12 months of age and older
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10069628 Varicella immunization LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000744-28 Sponsor Protocol Number: X06-Z-305 Start Date*: 2007-09-21
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX ®, in subjects ≥ 7...
    Medical condition: Herpes zoster [shingles] and post-herpetic neuralgia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 19:55:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA